Newborn use only

Alert	Remifentanil is a Schedule 8 drug.		
7.1.0.1	Chest wall rigidity has been reported in 10–20% of infants given it as a bolus (over <60 seconds)		
	or at higher dose, particularly in preterm infants.	-	
	naloxone and muscle relaxants.	5 ,	
Indication	Premedication for non-emergency intubation;		
	Infusion for analgesia/sedation		
Action	Remifentanil is a potent μ receptor agonist with rapid onset of action — peak analgesic action within 1 minute. Rapidly metabolised into inactive metabolites by non-specific plasma esterases with a half-life of 3-5 minutes.		
Drug Type	Remifentanil is a synthetic opioid analgesic drug related to fentanyl.		
Trade Name	DBL Remifentanil, Remifentanil Alphapharm, Remifentanil APOTEX, Remifentanil-AFT, Ultiva.		
Presentation	Remifentanil Powder [remifentanil hydrochloride] for infusion 1 mg, 2 mg, 5 mg.		
	Also contains glycine, hydrochloric acid and/or sodium hydroxide.		
Dosage	Premedication for intubation:		
	1 to 3 microgram/kg; may be repeated in 2–3 minutes if needed.		
	Infusion for analgesia in spontaneously breathin	_	
	0.03 microgram/kg/minute as intravenous infusion [highest safe dose unknown].		
	Infusion for analgesia/sedation in ventilated infants:		
	0.15–1 microgram/kg/minute as intravenous infusion.		
Maximum daily	1 microgram/kg/minute.		
dose			
Route	Intravenous.		
Preparation	IV bolus as premedication for intubation	1	
	STEP 2: Draw up 0.5 mL (500 microgram) of the above solution and add 9.5 mL glucose 5% or sodium chloride 0.9% to make a final volume of 10 mL with a concentration of 50 microgram/mL STEP 3: From the above solution, draw up 0.2 mL (10 microgram) and add 9.8 mL glucose 5% or sodium chloride 0.9% to make a final volume of 10 mL with a concentration of 1 microgram/mL. IV infusion for spontaneously breathing infants (≥ 2.5 kg only)		
	2-STEP DILUTION		
	Prescribed amount	Infusion rate	
	200 microgram/kg remifentanil and make up to	0.5 mL/hour = 0.03 microgram/kg/min	
	50 mL with glucose 5% or sodium chloride 0.9%		
	Step 1: Add 1 mL of water for injection to 1 mg vial of remifentanil to make a 1 mg/mL solution. Step 2: From the above solution, draw up 0.2 mL/kg (200 microgram/kg) and further dilute with glucose 5% or sodium chloride 0.9% to make a final volume of 50 mL. Infusing at a rate of 0.5 mL/hour = 0.03 microgram/kg/minute. IV infusion for analgesia/sedation in ventilated infants		
	IV infusion for analgesia/sedation in ver	· ·	
		_	
	IV infusion for analgesia/sedation in ver	· ·	

Newborn use only

	Step 1: Add 1 mL of water for injection to 1 mg vial of remifentanil to make a 1 mg/mL solution.
	Step 2: From the above solution draw up 3 mL/kg (3 mg/kg) and further dilute with glucose 5%
	or sodium chloride 0.9% to make a final volume of 50 mL. Infusing at a rate of 1 mL/hour = 1
	microgram/kg/minute.
Administration	IV BOLUS: Administer over at least 1 minute. Flush with 1 mL of sodium chloride 0.9%. Onset of
	action is immediate. Half-life is approximately 3–10 minutes.
	CONTINUOUS IV INFUSION : Via syringe driver. Upon ceasing the continuous infusion, flush the
	line with 1 mL of sodium chloride 0.9% over 1 hour.
	Note: It is advisable to use a dedicated IV line where possible.
Monitoring	Full cardiorespiratory monitoring.
	Monitor for urinary retention.
Contraindications	Known hypersensitivity to fentanyl or remifentanil.
Precautions	Rapid injection (<60 seconds) of remifentanil is associated with chest wall rigidity.
	Remifentanil in a bolus dose of 5 microgram/kg may cause hypotension.
Drug Interactions	Remifentanil enhances the action of other sedatives and hypnotics.
	Cardiovascular effects may be enhanced by beta blockers and calcium channel blockers.
Adverse Reactions	Respiratory depression, chest wall rigidity (can be treated with naloxone and muscle relaxants),
	bradycardia and asystole (may respond to atropine), hypotension, postoperative hypertension.
Compatibility	Fluids: Glucose 5%, glucose 5% in sodium chloride 0.9%, sodium chloride 0.9%, sodium chloride
	0.45%, water for injection. Not tested with glucose 10%. 19
	Y-site: Aciclovir sodium, adrenaline (epinephrine) hydrochloride, alfentanil hydrochloride,
	amikacin sulfate, aminophylline, amiodarone hydrochloride, ampicillin sodium, azithromycin,
	aztreonam, buprenorphine hydrochloride, calcium gluconate, cefazolin sodium, cefepime
	hydrochloride, cefotaxime, cefotetan disodium, cefoxitin, ceftazidime, ceftriaxone sodium,
	cefuroxime, , ciprofloxacin, clindamycin phosphate, dexamethasone sodium phosphate, digoxin,
	dobutamine hydrochloride, dopamine hydrochloride, fentanyl, fluconazole, ganciclovir sodium,
	gentamicin sulfate, heparin sodium, hydrocortisone sodium succinate, imipenem-cilastatin
	sodium, insulin regular, isoprenaline hydrochloride, lidocaine (lignocaine) hydrochloride,
	magnesium sulfate, mannitol, methylprednisolone sodium succinate, metoclopramide
	hydrochloride, metronidazole, midazolam hydrochloride, milrinone lactate, morphine sulfate,
	netilmicin sulfate, nitroglycerin, noradrenaline (norepinephrine) bitartrate, octreotide acetate,
	ondansetron hydrochloride, pancuronium bromide, phenylephrine hydrochloride, piperacillin
	sodium-tazobactam sodium, potassium acetate, potassium chloride, potassium phosphates,
	ranitidine hydrochloride, rocuronium bromide, sodium acetate, sodium bicarbonate, sufentanil
	citrate, sulfamethoxazole-trimethoprim, theophylline, thiopental sodium, ticarcillin disodium-
	clavulanate potassium, tobramycin sulfate, vancomycin hydrochloride, vasopressin, vecuronium
	bromide, zidovudine.
Incompatibility	Amino acid/glucose and lipid infusion: No information.
	Propofol, amphotericin, chlorpromazine, diazepam, furosemide (frusemide).
Stability	Reconstituted product should be used promptly and any unused material discarded according to
•	local Schedule 8 drug policy.
Storage	Store below 25° C. The 1 mg presentation should be stored protected from light.
Special Comments	Treat chest wall rigidity with supportive measures, neuromuscular blocking agents or naloxone.
	Chest wall rigidity can last a few minutes.
	Duration of action 5 to 10 minutes.
Evidence	Efficacy and safety:
	Premedication for intubation:
	Remifentanil: In RCTs (LOE II): Badiee et al in 40 preterm infants undergoing the InSurE
	procedure compared remifentanil 2 microgram/kg over 2 minutes and atropine versus placebo
	and atropine. Infants who received remifentanil felt less pain but there was no difference in
	duration of endotracheal intubation procedure, number of attempts and oxygen desaturation
	between groups. Chest wall rigidity occurred in 4/20 infants and laryngospasm in 6 infants.[1]
	between groups. Chest wan rigidity occurred in 4/20 illiants and laryingospasin in 0 liliants.[1]

Newborn use only

Avino et al in 40 preterm infants undergoing elective intubation compared remifentanil 1 microgram/kg over 60 seconds and atropine versus morphine 100 microgram/kg, midazolam 50 microgram/kg and atropine. There was a similar incidence of >2 intubation attempts (4/20 vs 4/20) and no difference in intubation conditions, time or adverse events. Chest wall rigidity was reported in 2 infants receiving remifentanil.[2] Choong et al in 30 term and preterm infants undergoing elective intubation compared remifentanil 3 microgram/kg over 60 seconds and atropine versus fentanyl 2 microgram/kg over 60 seconds, succinylcholine 2 mg/kg and atropine 20 microgram/kg and reported no significant difference in time to intubation but better intubation conditions with fentanyl and succinylcholine. Chest wall rigidity was reported in 2/15 infants receiving remifentanil.[3]

Remifentanil combination: In RCTs (LOE II): Norman et al in 34 preterm infants undergoing elective intubation compared rapid sequence induction (RSI) with glycopyrrolate, thiopental 2-3 mg/kg, remifentanil 1microgram/kg (duration of administration not reported) and suxamethonium and versus atropine + morphine 0.3 mg/kg. RSI had superior intubation conditions, shorter duration of intubation and was associated with reduced duration of aEEG/EEG depression.[4, 5] Pereira e Silva et al in 20 preterm infants undergoing elective intubation compared remifentanil 1 microgram/kg and midazolam 200 microgram/kg over 60 seconds versus morphine 150 microgram/kg and midazolam 200 microgram/kg. Intubation conditions in the remifentanil group were significantly better than in the morphine group. A second intubation attempt was needed in 4 infants in the morphine group only.[6] Crawford et al in 24 infants and children undergoing elective intubation compared propofol 4.0 mg/kg and remifentanil 3 microgram/kg versus propofol 4.0 mg/kg and succinylcholine 2 mg/kg. Duration of apnoea and intubating conditions after propofol/remifentanil were similar to those after propofol/succinylcholine. Bradycardia, hypotension and chest wall rigidity did not occur.[7] Conclusion: Remifentanil 1 to 3 microgram/kg infused over at least 60 seconds reduces but does not abolish infant pain during intubation. Studies using remifentanil as a single agent in preterm infants report chest wall rigidity in 10–20% of infants. Studies using remifentanil with another analgesic/sedative (midazolam or propofol) and/or succinylcholine have not reported chest wall rigidity as a problem. (LOE II GOR D) Further trials are required to assess the safety of remifentanil and determine the optimal intubation combination for newborn infants.

Analgesia/sedation for ventilation:

Remifentanil: In RCTs: Welzing et al in 23 term infants on mechanical ventilation compared remifentanil 0.15 microgram/kg/min adjusted in steps of 0.05 microgram/kg/min versus fentanyl 0.05 microgram/kg/min and midazolam 0.8 microgram/kg/min adjusted in steps of 0.02 microgram/kg/min. Remifentanil infusion was increased by 24% and fentanyl by 47%. Median extubation time shorter with remifentanil (80.0 versus 782.5 min, p=0.005).[8]

Remifentanil combination: In RCTs: Pereira e Silva et al in 20 preterm infants managed with mechanical ventilation and surfactant compared remifentanil 1 microgram/kg and midazolam 200 microgram/kg for intubation then remifentanil 0.5 microgram/kg/min infusion versus morphine 150 microgram/kg and midazolam 200 microgram/kg for intubation then morphine 10 microgram/kg/hour infusion. The remifentanil group had a shorter time to awaken (1173 \pm 608 versus 62 \pm 56.7 mins) and extubation (1320 \pm 650 versus 106.3 \pm 82.8 mins).[9]

Conclusion: Remifentanil 0.15 to 1 microgram/kg/min has been used for analgesia/sedation for ventilation and is associated with a shorter time to extubation than other opioids and midazolam. Chest wall rigidity has not been reported from remifentanil continuous infusion. (LOE II GOR B)

Analgesia/sedation for procedures

Laser for ROP: In RCTs: But et al in 91 preterm infants undergoing laser for ROP compared anaesthesia induced with midazolam 0.1 mg/kg and remifentanil 2 microgram/kg maintained

Newborn use only

with midazolam 0.1-0.2 mg/kg/hour and remifentanil 0.125-0.2 microgram/kg/min versus anaesthesia induced with 45% O₂ + 55% N₂O + 3-5% sevoflurane and fentanyl 1 microgram/kg maintained with 45% O_2 + 55% N_2O + 1–3% sevoflurane. There was no difference in complications or extubation time and mean arterial pressure values higher in remifentanil group only at 60 minutes.[10] Two case series reported analgesia/sedation with remifentanil alone or in combination in preterm infants undergoing laser for ROP. Demiel et al in 64 infants assessed remifentanil infusion 0.2 microgram/kg/min titrated up to 0.6 microgram/kg/min. Remifentanil was infused at a mean rate 0.4 ± 0.1 microgram/kg/min. No major adverse effects were observed except two patients with reversible bradycardia and hypotension. Premature infant pain profile scores revealed no pain. Extubation time was 189 ± 110 minutes.[11] Costamagna et al in 46 infants assessed propofol 3 to 4 microgram/kg bolus for intubation, then infusion of remifentanil 0.2 to 4 microgram/kg/min and propofol 2 to 20 mg/kg/hour. All the patients maintained haemodynamic stability. 21/36 patients in spontaneous ventilation before surgery were extubated within 24 hours (58.3%), 14/36 were extubated after 24 hours (38.8%) and one patient could not be extubated.[12] Conclusion: Remifentanil 0.2 to 0.6 microgram/kg/min has been used for analgesia/sedation for ventilated preterm infants undergoing laser for ROP and is associated with relatively short time to extubation. (LOE IV GOR C)

Insertion of PICC: In RCTs: Lago et al in 54 preterm spontaneously breathing undergoing PICC insertion compared remifentanil 0.03 microgram/kg/min versus placebo and sucrose and non-nutritive sucking. Remifentanil reduced NIPP and PIPP scores and cardiovascular and movement response to PICC insertion but did not make the PICC easier or quicker.[13] Shin et al in 14 mechanically ventilated preterm infants compared remifentanil 0.1 microgram/kg/min versus 0.25 microgram/kg/min. There was no difference in the Premature Infant Pain Profile; there were three episodes of apnoea (42.9%) and one of bradycardia (14.3%) in the high-dose group.[14] Conclusion: Remifentanil 0.03 microgram/kg/min reduces pain scores and cardiovascular response to PICC insertion but may not make the PICC easier or quicker. (LOE II GOR C).

Surgery: In RCTs: Davis et al in 60 infants undergoing pyloromyotomy compared remifentanil begun at 0.4 microgram/kg/min versus halothane expired concentration targeted 0.4% for maintenance anaesthesia. There was no difference in haemodynamic values, extubation times, discharge times, pain medications and adverse events between groups. There were no abnormal postoperative pneumograms in the remifentanil group versus three in the halothane group.[15] **Conclusion:** Remifentanil begun at 0.4 microgram/kg/min is an alternative to inhalational anaesthetic for infants undergoing surgical procedures and is not associated with adverse respiratory effects post-extubation. (LOE II GOR C)

Pharmacokinetics and pharmacodynamics:

Neonates and infants younger than 2 months of age had an enhanced clearance compared with older children indicating a high non-specific esterase activity already in very preterm infants.[16] The half-life in infants under 2 months was 5.4 ± 1.8 minutes.[17,20] Remifentanil in a bolus dose of 5 microgram/kg caused hypotension.[16, 17]

Dilution:

Drug stability data is only available for remifentanil diluted to 20 to 250 microgram/mL in a compatible fluid. ^{18, 19} The product excipients and drug properties of remifentanil do not suggest that the drug would be unstable at a concentration which is lower than this range. A lower final concentration of 5 microgram/mL was chosen for this formulary to aid accurate dosing and administration.

References

1. Badiee Z, Vakiliamini M, Mohammadizadeh M. Remifentanil for endotracheal intubation in premature infants: A randomized controlled trial. Journal of research in pharmacy practice. 2013;2:75-82.

Newborn use only

- 2. Avino D, Zhang WH, De Ville A, Johansson AB. Remifentanil versus morphine-midazolam premedication on the quality of endotracheal intubation in neonates: A noninferiority randomized trial. Journal of Pediatrics. 2014;164:1032-7.
- 3. Choong K, AlFaleh K, Doucette J, Gray S, Rich B, Verhey L, Paes B. Remifentanil for endotracheal intubation in neonates: a randomised controlled trial. Archives of disease in childhood Fetal and neonatal edition. 2010;95:F80-4.
- 4. Norman E, Wikstrom S, Hellstrom-Westas L, Turpeinen U, Hamalainen E, Fellman V. Rapid sequence induction is superior to morphine for intubation of preterm infants: A randomized controlled trial. Journal of Pediatrics. 2011;159:893-9.e1.
- 5. Norman E, Wikstrom S, Rosen I, Fellman V, Hellstrom-Westas L. Premedication for intubation with morphine causes prolonged depression of electrocortical background activity in preterm infants. Pediatric research. 2013;73:87-94.
- 6. Pereira e Silva Y, Gomez RS, Marcatto Jde O, Maximo TA, Barbosa RF, Simoes e Silva AC. Morphine versus remifentanil for intubating preterm neonates. Archives of disease in childhood Fetal and neonatal edition. 2007;92:F293-4.
- 7. Crawford MW, Hayes J, Tan JM. Dose-response of remifentanil for tracheal intubation in infants. Anesth Analg. 2005;100:1599-604.
- 8. Welzing L, Kribs A, Huenseler C, Eifinger F, Mehler K, Roth B. Remifentanil for INSURE in preterm infants: a pilot study for evaluation of efficacy and safety aspects. Acta paediatrica (Oslo, Norway: 1992). 2009;98:1416-20.
- 9. e Silva YP, Gomez RS, Marcatto Jde O, Maximo TA, Barbosa RF, e Silva AC. Early awakening and extubation with remifentanil in ventilated premature neonates. Paediatric anaesthesia. 2008;18:176-83.
- 10. But A, Arikan M, Aslan B, Ozturk L, Tabuk M, Horasanli E. Comparison of anesthesia with sevooflurane-N₂O and midazolam-remifentanil in low-birth-weight premature infants undergoing diode laser photocoagulation. Turkish Journal of Medical Sciences. 2012;42:573-9.
- 11. Demirel N, Bas AY, Kavurt S, Celik IH, Yucel H, Turkbay D, Hekimoglu E, Koc O. Remifentanil analgesia during laser treatment for retinopathy of prematurity: a practical approach in neonatal intensive care unit. American journal of perinatology. 2014;31:983-6.
- 12. Costamagna I, Garra R, Sbaraglia F, De Angelis A, Idone FA, Sammartino M. Total intravenous anaesthesia with propofol/remifentanil in preterms undergoing lasertherapy for retinopathy of prematurity (ROP). European Journal of Anaesthesiology. 2014;31:164.
- 13. Lago P, Tiozzo C, Boccuzzo G, Allegro A, Zacchello F. Remifentanil for percutaneous intravenous central catheter placement in preterm infant: a randomized controlled trial. Paediatric anaesthesia. 2008;18:736-44.
- 14. Shin SH, Kim HS, Lee J, Choi KY, Lee JH, Kim EK, Park MS, Choi JH. A comparative study of two remifentanil doses for procedural pain in ventilated preterm infants: a randomized, controlled study*. Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2014;15:451-5.
- 15. Davis PJ, Galinkin J, McGowan FX, Lynn AM, Yaster M, Rabb MF, Krane EJ, Kurth CD, Blum RH, Maxwell L, Orr R, Szmuk P, Hechtman D, Edwards S, Henson LG. A randomized multicenter study of remifentanil compared with halothane in neonates and infants undergoing pyloromyotomy. I. Emergence and recovery profiles. Anesth Analg. 2001;93:1380-6, table of contents.
- 16. Ziesenitz VC, Vaughns JD, Koch G, Mikus G, van Den Anker JN. Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. Clinical Pharmacokinetics. 2017:1-25.
- 17. Ross AK, Davis PJ, Dear Gd GL, Ginsberg B, McGowan FX, Stiller RD, Henson LG, Huffman C, Muir KT. Pharmacokinetics of remifentanil in anesthetized pediatric patients undergoing elective surgery or diagnostic procedures. Anesth Analg. 2001;93:1393-401, table of contents.
- 18. Australian Injectable Drugs Handbook. 7th ed. Remifentanil. Accessed on 12 April 2019.

Newborn use only

19. Micromedex. Remifentanil HCl. Accessed on 12 April 2019.	
20. Kumar P, Denson SE, Mancuso TJ. Premedication for nonemergency endotracheal intubation	
in the neonate. Pediatrics. 2010 Mar 1;125(3):608-15.	

Original: 1.0	12/04/2019
Revised: 1.1	30/04/2019
Current: 2.0	26/08/2021
Review	26/08/2026
INCOICO	20,00,2020

Authors Contribution

Original author/s	David Osborn, Srinivas Bolisetty
Evidence Review	David Osborn
Expert review	
Nursing Review	Eszter Jozsa, Kirsty Minter, Priya Govindaswamy
Pharmacy Review	Michelle Jenkins, Jing Xiao, Cindy Chen
ANMF Group contributors	Nilkant Phad, Bhavesh Mehta, John Sinn, Cindy Chen, Mohammad Irfan Azeem, Michelle Jenkins, Simarjit Kaur, Joanne Malloy, Thao Tran, Helen Huynh
Final editing and review of the original	Ian Whyte
Electronic version	Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty